Summary & Overview
HCPCS J1596: Injection of Glycopyrrolate, 0.1 mg
HCPCS Level II code J1596 denotes an injection of glycopyrrolate, 0.1 mg, a short-acting anticholinergic medication used in clinical settings for conditions requiring antimuscarinic effects. Nationally, accurate coding of injectable drugs like glycopyrrolate is important for clinical documentation, billing integrity, and program compliance given variable payer policies and unit-based pricing.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and the clinical context in which J1596 is used. The publication summarizes common payer considerations, prevailing billing practices, and benchmark elements relevant to this HCPCS Level II drug code.
This resource outlines the benchmarks and policy-relevant points readers should expect: definitions and usage of the code, payer coverage themes, billing nuances tied to injectable drug units, and common modifiers used with drug administration lines. Where input data was not provided, the document notes its absence. The summary is intended to help coding professionals, billing staff, and policy analysts locate key information about HCPCS Level II code J1596 quickly and apply it in a national context.
Billing Code Overview
HCPCS Level II code J1596 represents an injection of glycopyrrolate, 0.1 mg. This code describes a billed drug administration for a specific unit of the anticholinergic agent glycopyrrolate.
-
Service type: Drug administration/injection
-
Typical site of service: Ambulatory clinic, hospital outpatient department, or other outpatient infusion/administration settings where injectable medications are given
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with symptomatic drooling (sialorrhea) related to neurologic conditions such as Parkinson disease, amyotrophic lateral sclerosis, cerebral palsy, or post-stroke dysphagia. The patient is evaluated in a neurology or physiatry clinic and deemed a candidate for anticholinergic therapy to reduce salivary secretions. Glycopyrrolate injection J1596 is prepared and administered by a qualified clinician (neurologist, physiatrist, pediatrician for pediatric cases, or anesthesiologist in procedural settings) in an outpatient infusion clinic, ambulatory surgery center, or hospital inpatient unit.
The clinical workflow: evaluation and consent are completed in clinic; baseline vital signs and airway assessment are documented; medication is prepared by pharmacy or nursing per facility protocol; J1596 (dosing per manufacturer and patient weight/age) is administered via intramuscular or intravenous injection per prescribing instructions; patient is monitored for anticholinergic adverse effects (tachycardia, urinary retention, blurred vision, dry mouth) for an appropriate observation period; documentation includes indication, dosage, route, lot number, and patient response. Billing captures J1596 with appropriate diagnosis linkage and any applicable modifiers for service circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|